Endoscopy 2018; 50(04): S9-S10
DOI: 10.1055/s-0038-1637051
ESGE Days 2018 oral presentations
20.04.2018 – Upper GI: resection session 1
Georg Thieme Verlag KG Stuttgart · New York

ENDOSCOPIC TREATMENT OF PATIENTS WITH HIGH-RISK EARLY ESOPHAGEAL CANCER

M Kollar
1   Institute for Clinical and Experimental Medicine, Department of Clinical and Transplant Pathology, Prague, Czech Republic
,
J Krajciova
2   Institute for Clinical and Experimental Medicine, Department of Hepatogastroenterology, Prague, Czech Republic
,
J Maluskova
1   Institute for Clinical and Experimental Medicine, Department of Clinical and Transplant Pathology, Prague, Czech Republic
,
A Pazdro
3   1st Faculty of Medicine, Charles University in Prague and Motol University Hospital, Third Department of Surgery, Prague, Czech Republic
,
T Harustiak
3   1st Faculty of Medicine, Charles University in Prague and Motol University Hospital, Third Department of Surgery, Prague, Czech Republic
,
D Kodetova
4   2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Department of Pathology and Molecular Medicine, Prague, Czech Republic
,
Z Vackova
2   Institute for Clinical and Experimental Medicine, Department of Hepatogastroenterology, Prague, Czech Republic
,
J Spicak
2   Institute for Clinical and Experimental Medicine, Department of Hepatogastroenterology, Prague, Czech Republic
,
J Martinek
2   Institute for Clinical and Experimental Medicine, Department of Hepatogastroenterology, Prague, Czech Republic
› Author Affiliations
Further Information

Publication History

Publication Date:
27 March 2018 (online)

Also available at
 
 

    Aims:

    The aim of this study was to assess outcomes of endoscopic treatment in patients with 'high-risk' early esophageal cancer (EEC). 'High-risk' cancer was defined as any cancer with sm invasion or mucosal cancer with at least one of the following: poor differentiation, invasion to blood or lymphatic vessels and high tumor cell dissociation. The main outcome measurement was tumor-free survival.

    Methods:

    A single-center, retrospective analysis of prospectively collected data. Patients with EEC underwent endoscopic resection or endoscopic submucosal dissection. Based on histopathological staging, patients with 'high-risk' EEC without contraindications were referred for surgery. The patients have been followed up for a median of 39 months (2 – 156).

    Results:

    A total of 56 patients with ‘high-risk’ EEC underwent endoscopic treatment: 21 patients (41%) had T1a cancer with ‘high-risk’ features and 35 patients (59%) had T1b cancer with sm invasion (sm1: 15, sm2: 9, sm3: 11); 19 patients were referred for surgery. A total of 37 patients (66%) continued in endoscopic treatment. Complete local remission (CLR) of neoplasia was achieved in 35/37 patients (95%). Tumor generalization occurred in 2 patients (one of them achieved CLR) 24 months after endoscopic treatment (both patients had sm3 invasion) and these patients are undergoing oncological treatment. All remaining patients with CLR (n = 33) have experienced neither local relapse nor generalization. Tumor-free survival was 89% in patients treated endoscopically and endoscopy related mortality was 0% (0/37).

    Among 19 patients who were referred for esophagectomy, one patient presented with tumor generalization revealed during the operation. The remaining 18 patients underwent esophagectomy; local residua of malignancy were present in 5/18 patients. Lymph node (LN) metastases have not been detected in any patient among the 337 examined LNs.

    Conclusions:

    Endoscopic treatment provides long-term remission or cure in a considerable number of patients with ‘high-risk’ EEC and it may thus represent a valid alternative to surgery.


    #